Gastrointestinal Oncology
The sponsor focuses on digestive system tumours, with particular attention to metastatic colorectal cancer and advanced colon and rectal adenocarcinoma. Its research activity is centred on patients receiving systemic treatment for stage IV colorectal cancer.
- Colorectal cancer
- Metastatic disease
- Digestive tumours
Clinical interest is directed toward disease settings where tumour burden and treatment-related complications intersect in advanced gastrointestinal cancer.
Thrombosis Prevention
Another key area is the prevention of venous thromboembolic disease in oncology patients, especially those with metastatic colorectal cancer beginning first-line treatment. The sponsor’s research activity includes strategies aimed at reducing symptomatic and incidental VTE.
- Venous thromboembolism
- VTE prophylaxis
- Oncology-associated thrombosis
This area reflects a strong therapeutic interest in complications that affect treatment safety in advanced cancer care.
Anticoagulation in Cancer Care
The sponsor is involved in research on low molecular weight heparin use within oncology, with attention to tinzaparin as a preventive approach in patients with advanced colorectal malignancy. This places anticoagulant management within the context of cancer-associated thrombosis.
- Low molecular weight heparin
- Tinzaparin
- Antithrombotic therapy
Research in this domain aligns with the clinical need to address thrombotic risk during systemic cancer treatment.
Systemic Treatment Support
The clinical focus also extends to patients starting first-line systemic therapy for metastatic colorectal cancer, including treatment with chemotherapy and targeted therapy. The sponsor’s work is situated at the interface of anticancer treatment and supportive care.
- First-line systemic treatment
- Chemotherapy
- Targeted therapy
This area highlights interest in managing risks that arise during active oncologic therapy in advanced disease.
